The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Study Type
OBSERVATIONAL
Enrollment
20
Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
Cancer-directed therapy with intensive regimens ("7+3," Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care.
Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGNon-Relapse Mortality (NRM) in Frail, Pre-Frail, and Non-Frail patients
NRM will be defined as death without evidence of disease progression or relapse.
Time frame: 1-month
NRM by Intensity of Treatment
NRM of frail and pre-frail patients by intensity of treatment
Time frame: 1-month and 6-month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.